Clinical trials: Chronic Graft Vs. Host Disease
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Chronic Lymphocytic Leukemia
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether on course (6 cycles) of consolidation therapy with Revlimid can shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL) in the bone marrow.
- Trial name
- NCT01600053
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Kipps
Graft vs Host Disease, Graft-Versus-Host Disease
Pomalidomide for Chronic Graft-versus-Host Disease
Background: Pomalidomide is a drug that alters the body's immune response. It may help people who have chronic graft-versus-host disease (GvHD).
- Trial name
- NCT01688466
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
Primary Objective: The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic, Stem Cell Transplant Complications
- Trial name
- BOSTON-4 (NCT04107675)
- Testing
- Liposomal Cyclosporine A
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Zambon SpA
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Graft-versus-Host Disease, Stomatitis
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
This study was designed to be conducted in 2 parts. The first part is a pilot study to test the effects of topical thalidomide gel 20mg applied to up to 3 oral ulcers in patients who have developed oral chronic…
- Trial name
- NCT00075023
- Testing
- Thalidomide Gel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Nursing Research (NINR)
Chronic GVHD
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Background: Chronic Graft Versus Host Disease (cGVHD) can occur after a person has had a stem cell or bone marrow transplant. In cGVHD, the donor cells attack the recipient's body.
- Trial name
- NCT04294641
- Testing
- Ibrutinib, ECG, PFT's
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, JNS Kinase
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
Background: About half the people who have a hematopoietic stem cell transplant using donor cells get Chronic Graft Versus Host Disease (cGVHD). This is chronic graft versus host disease.
- Conditions
- Graft Versus Host Disease, JNS Kinase, Topical Administration
- Trial name
- NCT03395340
- Testing
- Ruxolitinib 1.5% cream, vehicle cream
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Chronic Low Back Pain
Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
This study is designed to examine brain properties for placebo response in chronic back pain patients. The investigators have preliminary data indicating that, in blinded clinical trial studies with neutral instructions regarding…
- Trial name
- NCT02013427
- Testing
- Naproxen, Omeprazole
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Northwestern University
Chronic Myelogenous Leukemia
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in…
- Trial name
- LASOR (NCT00802841)
- Testing
- nilotinib, imatinib
- Where
- 56 sites in Argentina, Brazil and 10 more
- Volunteers
- 191 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic Hepatitis B Atypical
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection
- Trial name
- NCT02981602
- Testing
- IONIS-HBVRx
- Where
- 7 sites in Hong Kong, South Korea
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Chronic Graft-versus-host Disease
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD.
- Trial name
- NCT01226420
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Low Back Pain, Patient Acceptance of Health Care
Veterans Response to Dosage in Chiropractic Therapy
This study evaluates how Veterans with chronic low back pain (cLBP) respond to varying doses of chiropractic therapy and how health services utilization are impacted as a result. There are 2 phases in this study.
- Conditions
- Low Back Pain, Patient Acceptance of Health Care, Veterans Health
- Trial name
- VERDICT (NCT04087291)
- Testing
- Chiropractic Care
- Where
- 4 sites in United States
- Volunteers
- 766 people
- Sponsor
- Palmer College of Chiropractic
GVHD, Ocular Rosacea
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
The purpose of this study was to see if Intense Pulsed Light (IPL) can be used safely and effectively to help treat dry eyes from ocular rosacea after chronic graft-versus-host disease (GVHD).
- Conditions
- GVHD, Ocular Rosacea, Dry Eye Syndrome
- Trial name
- NCT02066051
- Testing
- IPL, Meibomian Gland Expression
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
The primary hypothesis of this research study is that patients in remission undergoing myeloablative haploidentical hematopoietic stem cell transplantation (HSCT) on the Thomas Jefferson University (TJU) 2 Step treatment regimen…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT01350245
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen